title: Effects of an anti-angiogenic agent, TNP-470, on the growth of oral squamous cell carcinomas.
abstract: Anti-tumor effects of an anti-angiogenic agent, TNP-470, on the growth of oral squamous cell carcinomas (SCCs) were evaluated in vivo and in vitro. The growth of an oral SCC cell line, HSC-2, inoculated subcutaneously in severe combined immuno-deficiency (SCID) mice was inhibited in a dose-dependent manner by the treatment with this agent. A reduction of microvessels surrounding tumor tissues treated with TNP-470 was observed by immunohistochemistry. Significant side-effects were not observed except for weight loss during the period of treatment with high dose (50 mg/kg) of TNP-470. The direct effects of TNP-470 on oral SCC cell lines were also evaluated in culture. The growth of all eight SCC cell lines tested was inhibited by TNP-470, but the sensitivity of the oral SCC cell lines to TNP-470 was about 1700 times less than that of endothelial cells. These results suggest that TNP-470 inhibits the growth of oral SCC by anti-angiogenic activities and that it may be effective as a new therapy of oral cancer.
authors.affiliation: First Department of Oral and Maxillofacial Surgery, School of Dentistry, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima City, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Ueda
authors.forename: N
authors.initials: N
authors.lastname: Kamata
authors.forename: E
authors.initials: E
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Yokoyama
authors.forename: T
authors.initials: T
authors.lastname: Hoteiya
authors.forename: M
authors.initials: M
authors.lastname: Nagayama
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division; D003510:Cyclohexanes; D004354:Drug Screening Assays, Antitumor; D007150:Immunohistochemistry; D051379:Mice; D016513:Mice, SCID; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
chemical_list: D020533:Angiogenesis Inhibitors; D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000077609:O-(Chloroacetylcarbamoyl)fumagillol